Actively Recruiting

Age: 18Years +
All Genders
ID06299540

Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice

Led by Janssen Cilag S.A.S. · Updated on 2026-06-05

180

Participants Needed

1

Research Sites

56 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying how an individual physical activity intervention (IPAI) affects health-related quality of life (HRQoL) in people with chronic lymphocytic leukemia (CLL) who are starting or have recently started treatment with ibrutinib. The goal is to see if this physical activity program can improve quality of life during routine clinical care. HRQoL will be measured using the Functional Assessment of Cancer Therapy - General scale (FACT-G). Participants with CLL will be invited to follow a tailored physical activity program that includes walking and twice-weekly remote adapted physical activity sessions. These sessions will be adjusted by a trainer to fit each person's abilities. The program lasts six months, with a first four-month supervised phase and a following two-month unsupervised phase to encourage independence. Participants in a comparison group will continue their usual physical activity and medical care. Throughout the study, participants will wear a connected watch continuously to monitor activity and sleep. Researchers will assess changes in quality of life, fatigue, sleep, anxiety, depression, and physical fitness at baseline, 4.5 months, 6.5 months, and 12 months. Additional measures include treatment-related events and adherence to the physical activity program. The study aims to collect comprehensive data on how the intervention impacts participants’ well-being and daily function over time.

CONDITIONS

Brief Title

Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants newly treated with ibrutinib for first line or relapsed chronic lymphocytic leukemia (treatment started within the last 8 days)
  • Participants agreed to follow the individual physical activity intervention (IPAI)
  • Participants have access to a compatible electronic device such as a smartphone, laptop, or tablet
  • Participants have internet access at home and an email address
  • Participants agreed to wear a connected watch 24 hours a day for the duration of the study
Not Eligible

You will not qualify if you...

  • Pregnant participants or those planning to become pregnant during the study
  • Participants unable or considered unsafe to practice physical activity
  • Participants who have received an investigational drug or invasive investigational device within 90 days before inclusion
  • Participants currently involved in another interventional study
  • Participants with probable difficulties in using the digital tool independently

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Outpatient Treatment

Duration - 6 months

Participants follow an individual physical activity intervention consisting of a supervised 4-month program followed by a 2-month unsupervised program to encourage physical activity in addition to their routine medical treatment.

Weekly remote adapted physical activity sessions (2 sessions per week) and regular assessments at baseline, Month 4.5, and Month 6.5

Follow-up Monitoring

Duration - 6 months

Participants are monitored for health-related quality of life and physical activity outcomes up to 12 months after starting the intervention.

Assessments at Month 6.5 and Month 12

Trial Site Locations

Total: 1 location

1

Institut Universitaire du Cancer Toulouse Oncopole

Toulouse, France, 31059

Actively Recruiting

Loading map...

Research Team

S

Study Contact

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Real-World Study of Fixed-Duration Ibrutinib plus Venetoclax...

Leukemia, Lymphocytic, Chronic, B-Cell

Actively Recruiting

1 location

A Phase 3, Open-label, Randomized Study Comparing Nemtabruti...

Leukemia, Lymphocytic, Chronic, B-Cell

Actively Recruiting

54 locations

Multicohort Study to Customize Ibrutinib Treatment Regimens ...

Leukemia, Lymphocytic, Chronic, B-Cell

Actively Recruiting

74 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here